Stay up-to-date with the latest news and information from the drug testing industry by subscribing to Results, our monthly newsletter.
Your Privacy Choices | Privacy Notices | Privacy Shield | Terms | Language Assistance / Non-Discrimination Notice | Asistencia de Idiomas / Aviso de no Discriminación | 語言協助 / 不䈚視通知
Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks — ® and ™ — are the property of their respective owners. © 2000-2024 Quest Diagnostics Incorporated. All rights reserved.
Quest Diagnostics is pleased to announce that we now offer a synthetic cannabinoids (“K2/Spice”) testing panel. This new panel uses urine samples to test for commonly detected synthetic cannabinoid compounds including: AM-2201, JWH-018, JWH-019, JWH-073, JWH-250, UR-144 and XLR-11. UR-144 and XLR-11 are the newest compounds and are chemically different from the first generation compounds.
Synthetic cannabinoids have gained media attention as a “legal high.” While most of the substances are not actually cannabinoids, they act on the same receptor in the human body as Δ9‐tetrahydrocannabinol (THC), the main active ingredient in marijuana and produce similar psychoactive effects. It is estimated that synthetic cannabinoids are anywhere between four and fifty times more potent than marijuana.
Manufacturers of synthetic drugs continually change their products to stay ahead of regulators. Reliable, timely drug testing is critical to protect public and workplace safety and to help enforce laws at the state and federal level. Our scientific experts continue to monitor and adjust our testing panels for new illicit substances in the marketplace.
For more information about drug testing, visit our website or contact us online.